Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEH200521 (18F) and GEH200520 in Healthy Volunteers
NCT06398730Phase 1Completed
- Sponsor
- GE HealthCare
- Start
- Jul 2024
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GEH200521 and GEH200520 (7 arms), sponsored by GE HealthCare. Primary endpoint: Incidence of all Treatment-Emergent Adverse Events at 7 days. Started Jul 2024; status: completed.
02
Drugs
GEH200521GEH200520
Beyond the preview
Go deeper on NCT06398730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398730.